Glenmark Pharmaceuticals Inc., USA (Glenmark) has introduced latanoprost ophthalmic solution, 0.005% (0.05 mg/mL), expanding its ophthalmic product portfolio.
Equivalent to Xalatan
The newly launched latanoprost ophthalmic solution is bioequivalent and therapeutically equivalent to Xalatan ophthalmic solution, 0.005%, developed by Upjohn US 2 LLC.
Market Overview
According to IQVIA sales data for the 12-month period ending December 2024, the market for Xalatan ophthalmic solution, 0.005%, recorded annual sales of approximately $113.5 million.
Company Statement
Marc Kikuchi, President & Business Head, North America, expressed enthusiasm about the launch, stating, “We are excited to introduce our fourth ophthalmic product, latanoprost ophthalmic solution, 0.005% (0.05 mg/mL). This addition strengthens our ophthalmic portfolio and underscores our commitment to addressing market needs with high-quality solutions.”
About Glenmark Pharmaceuticals
Glenmark Pharmaceuticals Ltd. is a research-driven global pharmaceutical company with a strong presence in branded, generic, and over-the-counter (OTC) segments.
As reported by pharmabiz.com, the company focuses on key therapeutic areas, including respiratory, dermatology, and oncology.